Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers
- 23 December 2002
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 24 (1), 37-43
- https://doi.org/10.1002/bdd.336
Abstract
Ketamine is known to provide analgesic effects without an anesthetic when administered in a low dose. We previously reported that a tablet containing ketamine had analgesic effects in patients with neuropathic pain. In the present study, we compared the plasma concentration profiles of the enantiomers of ketamine and its active metabolite, norketamine, up to 8 h after the administration of 20 mg of ketamine by injection, after the administration of two tablets containing 25 mg of ketamine, after the administration of two sublingual tablets containing 25 mg of ketamine, after the insertion of a suppository containing 50 mg of ketamine, and after the application of a nasal spray containing 25 mg of ketamine to three healthy volunteers. The plasma concentration of ketamine biexponentially declined after the administration by injection; the value of T1/2β for ketamine was approximately 120 min. The bioavailability of the tablet was estimated to be approximately 20%; the area under the plasma concentration–time curve, (AUC)0→8 h, of norketamine was approximately 500 ng h/ml in both enantiomers. The bioavailabilities of the sublingual tablet and the suppository were estimated to both be approximately 30%; the AUC0→8 h of norketamine was 280–460 ng h/ml in both enantiomers. The plasma concentration profiles of the sublingual tablet and the suppository were almost similar to that of the tablet. The bioavailability of the nasal spray was estimated to be approximately 45%, which was the highest value among the preparations tested, and the AUC0→6 h of norketamine was low (approximately 100 ng h/ml) in both enantiomers. These pharmacokinetic findings suggested that all of the ketamine preparations tested in this study may be useful for the alleviation of neuropathic pain. We propose that the type of ketamine preparation should be selected in accordance with the patient's disease condition and the required dosage amount of ketamine. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 16 references indexed in Scilit:
- Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketaminePain, 1999
- Oral ketamine therapy in the treatment of postamputation stump painActa Anaesthesiologica Scandinavica, 1997
- Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in childrenBritish Journal of Anaesthesia, 1996
- Ketamine Injection Used OrallyPalliative Medicine, 1996
- Continuous subcutaneous administration of the N -methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgiaPain, 1995
- Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial painPain, 1995
- Ketamine: an update on the first twenty-five years of clinical experienceCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1989
- Ketamine—Its Pharmacology and Therapeutic UsesAnesthesiology, 1982
- PHARMACOKINETICS AND ANALGESIC EFFECTS OF I.M. AND ORAL KETAMINEBritish Journal of Anaesthesia, 1981
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981